To include your compound in the COVID-19 Resource Center, submit it here.

FDA accepts NDA from Therevance and Mylan for COPD candidate revefenacin

Theravance Biopharma Inc. (NASDAQ:TBPH) and partner Mylan N.V. (NASDAQ:MYL)

Read the full 90 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE